Venture funding for life science companies plummets in Q2, says report
This article was originally published in Scrip
US venture capital investment in life science companies declined for the fourth quarter in a row – a predictable drop considering the limitations on exit strategies – plunging 39% on a year-over-year basis during the second quarter of 2012 while VC dollars across all industries fell just 12% in the same timeframe.
You may also be interested in...
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
In its first ASH since acquiring Celgene and with competitors coming, Bristol presented pivotal results for liso-cel (JCAR017) that support a year-end US FDA submission as bb2121 nears a first-half of 2020 filing.